Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 4NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 10Other hematologic neoplasm 6CNS 5Thoracic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Myeloid 1Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Carboplatin 62Paclitaxel 61Specimen Handling 37Cisplatin 37Taxes 35Magnetic Resonance Spectroscopy 31Bevacizumab 30Immunoglobulin G 23Disulfides 23Biopsy 22Cyclophosphamide 19aldesleukin 17Topotecan 16Brachytherapy 16Radiotherapy 15Gemcitabine 15veliparib 14Oxaliplatin 13Doxorubicin 13temsirolimus 12fludarabine 12Platinum 12Docetaxel 121,2-diaminocyclohexaneplatinum II citrate 12olaparib 11liposomal doxorubicin 10cediranib 10Sirolimus 10Radiation 9Nivolumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × etoposide phosphate × Gynecologic × Clear all
NCT00003064 2014-01-06

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 1/2 Unknown
30 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡